Skip to main content

Response-Adapted PULSAR Radiotherapy

Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)

  • RegistryNCT07139990
  • PhasePhase 1
  • StatusRecruiting
  • ConditionExtensive-Stage SCLC, Brain Metastases, Soft Tissue Sarcoma and Head and Neck Cancer
  • SponsorUniversity of Texas Southwestern Medical Center
How PRISM worksNCT071399901 min

What the film says

Read the transcript

This trial is for adults with several cancers, including extensive stage small cell lung cancer, brain metastases, soft tissue sarcoma and head and neck cancer.

The idea: personalize radiotherapy. Radiation is given as single high doses, called pulses, and later pulses are adapted to how each tumor responds on scans. Depending on the cohort, it is combined with chemoimmunotherapy or immunotherapy.

This phase 1 study plans 105 patients and looks at feasibility and safety. At UT Southwestern Medical Center in Dallas, Neil Desai leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT07139990

    Adults; cohorts include extensive stage SCLC, brain metastases, soft tissue sarcoma, head and neck cancer; Single high doses called pulses, adapted to response on scans; Combined with chemoimmunotherapy or immunotherapy by cohort; Phase 1; 105 patients; feasibility and safety (+1 more lines)

The drug

What is being tested.

Fractionated stereotactic radiosurgery (SRS, 5 doses total) for brain metastasis given in two "pulses" (3 fractions + 2 fractions) with second pulse adapted to interim radiographic response Adaptive Changes Allowed: Omission of 2nd "pulse" in >=25% responders or tumor target size/shape change in remainder

Radiographic response-adapted thoracic tumor radiotherapy given as single doses ('pulses') before standard of care chemoimmunotherapy cycles. Adaptive Changes Allowed: Tumor target (size/shape), # of doses (reduction) Adaptive Changes Allowed: Tumor target (size/shape), # of doses (reduction)

Cohort-Specific Rationale COHORT A (ES-SCLC Personalized ultrahypofractionated stereotactic ablative radiotherapy (PULSAR) Thoracic Tumor): Chemoimmunotherapy with 4-6 cycles of platinum/etoposide and PD-L1 (Programmed Death-Ligand 1 protein) inhibition has become the standard systemic therapy for extensive stage small cell lung cancer (ES-SCLC), based on modest but significant OS (overall survival) benefits seen with the addition of either atezolizumab or durvalumab to chemotherapy in the IMpower133 and CASPIAN trials, respectively.

The study

How the trial runs.

To characterize feasibility, safety, and/or preliminary efficacy of personalized strategies to adapt standard radiotherapy treatments to individual patient responses.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Performance status ECOG 0-2
  • Extensive stage small cell lung cancer diagnosed by tissue biopsy within 180 days of registration.
  • Patient must be planned for or receiving standard of care chemoimmunotherapy.
  • Patient must have received no more than 3 cycles by time of study enrollment.
  • Able and indicated according to investigator to receive thoracic radiotherapy
  • Diagnosis of solid tumor malignancy with MRI-defined brain metastasis lesions within 60 days of registration

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.